Novo Nordisk stripped comment
CSII for the treatment of diabetes (review) From:
Sent: 20 september 2007 11:41
To: christopher Feinmann
subject: CSII for the treatment of diabetes (review)

Attachments: Raslova errartum.pdf; Raslova_Diab_Res_clin_pract_66_(2004)
_ 193_201 - type 2.pdf

Dear Mr Feinmann

Thank you for the opportunity to review the assessment report for the continuous
subcutaneous insulin infusion for the treatment of diabetes. Are comments are
as follows:

a.. whilst it is correct that the fast-acting insulin analogues currently
available are aspart, lispro and glulisine, none of the studies referred to in
this report involve glulisine. We therefore feel that it is inappropriate to
include this insulin in the review of CSII therapy with analogue insulin.

b.. The report states that there is no evidence that MDI with analogue
insulins is superior to that with human insulins in type 2 patients, based on
the findings of the cochrane review by siebenhofer et all. However, we would
request that the Appraisal Committee also consider results of the study by
Raslova et a12,3 (references attached). This study showed that basal-bolus
therapy with insulin detemir and insulin aspart in type 2 patients gave
comparable glycaemic control to NPH and human soluble insulin, but with
significantly less nocturnal hypoglycaemia, less weight gain and lower
day-to-day variation in fasting plasma glucose. This study was not included in
the cochrane review as it's duration was 22 weeks, with siebenhofer et al only
considering studies of 24 weeks or longer.

Kind regards

1. siebenhofer A, plank J, BergholdA, JeitlerK, Horvath K, Narath M et al.
short acting insulin analogues versus regular human insulin in patients with
diabetes mellitus. Cochrane Database of systematic Reviews. Cochrane Database
of systematic Reviews 2006 Issue 2 chichester (UK): John wiley & Sons Ltd, 2006

2. Raslova K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu N. Insulin detemir and
insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes
Research and Clinical practice 66, 2004, 193-201

3. Raslova K, Bogoev M, Raz I, Leth G, Gall M-A, Hancu N. corrigendum to
"Insulin detemir and insulin aspart: A promising basal-bolus reglmen for type 2
diabetes". Diabetes Research and clinical practice 72, 2006, 112

«Raslova errartum.pdf» «Raslov~Diab_Res_clin_pract_66_(2004) _193_201 - type
2.pdf»

Novo Nordisk Ltd.
Broadfield Park

Brighton Road
crawley
West sussex RH11 9RT

united Kingdom
Registered office: No. 1118740

A changing Diabetes Bus world Tour
How can a bus help raise awareness about diabetes? Find out here
page 1

NOvo Nordisk stripped comment

This e-mail (including any attachments) is intended for the addressee(s) stated
above only and may contain confidential information protected by law. You are
hereby notified that any unauthorized reading, disclosure, copying or
distribution of this e-mail or use of information contained herein is strictly
prohibited and may violate rights to proprietary information. If you are not an
intended recipient, please return this e-mail to the sender and delete it
immediately hereafter. Thank you.

Delivered via MessageLabs

page 2